The US FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients.

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...

Geneos Wealth Management Inc. decreased its position in Sanofi (NASDAQ:SNY – Free Report) by 2.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 10,223 shares of the company’s stock ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from ...

Fifth Third Bancorp reduced its stake in Sanofi (NASDAQ:SNY – Free Report) by 9.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange ...

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...

By his estimate, that means AI has been around at Sanofi for about a third of the "discovery" process for some drugs. That ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

The Sanofi Pension Scheme has completed a £1.4bn buy-in with Legal & General (L&G) Assurance Society Limited, securing the benefits of 4,900 retirees and 5,600 deferred members ...